63 filings
ARS
2023 FY
ACRV
Acrivon Therapeutics Inc
26 Apr 24
Annual report to shareholders
8:36am
DEFA14A
ACRV
Acrivon Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
8:33am
DEF 14A
ACRV
Acrivon Therapeutics Inc
Definitive proxy
26 Apr 24
8:30am
8-K
ACRV
Acrivon Therapeutics Inc
24 Apr 24
Results of Operations and Financial Condition
4:01pm
S-3
ACRV
Acrivon Therapeutics Inc
Shelf registration
17 Apr 24
4:39pm
8-K
yobdba
9 Apr 24
Acrivon Therapeutics Announces $130 Million Private Placement Financing
7:05am
S-8
v46wt n5s0jn2lzh0d
29 Mar 24
Registration of securities for employees
9:06am
8-K
8k6z6t09cq6wk82oz30
28 Mar 24
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8:00am
8-K
xy12f
4 Mar 24
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
8:15am
8-K
fqfx rio9
8 Feb 24
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
8:27am
8-K
tzce3nw kw916m
8 Jan 24
Regulation FD Disclosure
7:28am
EFFECT
2mxm 64r8w2vo
18 Dec 23
Notice of effectiveness
12:15am
CORRESP
woalt k8af9438xbei0
12 Dec 23
Correspondence with SEC
12:00am
8-K
p16uxwicg 876
8 Dec 23
Entry into a Material Definitive Agreement
4:21pm
UPLOAD
plcq90zf
5 Dec 23
Letter from SEC
12:00am
S-3
80n j35hzds
1 Dec 23
Shelf registration
4:35pm
8-K
r0lymabnpmd86ennw71
9 Nov 23
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
9:12am
8-K
jye26f skbluydw52
5 Sep 23
Regulation FD Disclosure
5:23pm